<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639925</url>
  </required_header>
  <id_info>
    <org_study_id>FPCR1R2-1</org_study_id>
    <nct_id>NCT00639925</nct_id>
  </id_info>
  <brief_title>Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer</brief_title>
  <official_title>Phase I Sturdy on Antiangiogenic Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fukushima Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Center, Institute of Medical Science, University of Tokyo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fukushima Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, and tolerability of HLA-A*2402
      restricted epitope peptide VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in combination
      with gemcitabine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vascular endothelial growth factor receptor 1 and 2 (VEGFR1 andVEGFR2) are essential targets
      to tumor angiogenesis, and we identified that peptides derived from these receptors
      significantly induce the effective tumor specific CTL response in vitro and in vivo.
      According to these findings, in this trial, we evaluate the safety, tolerability and immune
      response of these peptide emulsified with Montanide ISA 51 in combination with gemcitabine
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse effect, toxicities as assessed by NCI CTCAE version3.0</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>feasibility</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Phase I study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VEGFR1-1084, VEGFR2-169, and gemcitabine</intervention_name>
    <description>One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8 and 15.</description>
    <arm_group_label>Phase I study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        DISEASE CHARACTERISTICS

        1. Locally advanced or metastatic pancreatic cancer precluding curative surgical resection
        and recurrent pancreatic cancer 2. Measurable disease by CT scan PATIENTS CHARACTERISTICS

          1. ECOG performance status 0-2

          2. Life expectancy &gt; 3 months

          3. Laboratory values as follows 2,000/mm3 &lt; WBC &lt; 15000/mm3 Platelet count ≥ 750,000/mm³
             Total Bilirubin ≤ 1.5 x Aspartate transaminase &lt; 150 IU/L Alanine transaminase &lt; 150
             IU/L Creatinine ≤ 3.0 mg/dl

          4. HLA-A*2402

          5. Able and willing to give valid written informed consent

        Exclusion Criteria:

          1. Pregnancy (women of childbearing potential: Refusal or inability to use effective
             means of contraception)

          2. Breast-feeder

          3. Active or uncontrolled infection

          4. Prior chemotherapy, radiation therapy, or immunotherapy within 4 weeks

          5. Serious or aggravated wound

          6. Active or uncontrolled other malignancy

          7. Steroids or immunosuppressing agent dependant status

          8. Interstitial pneumonia

          9. Ileus

         10. Decision of unsuitableness by principal investigator or physician-in-charge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsukazu Gotoh, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fukushima Medical University, First depertment of Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002 Dec;8(12):1369-75. Epub 2002 Nov 4.</citation>
    <PMID>12415261</PMID>
  </reference>
  <reference>
    <citation>Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006 Oct 1;12(19):5841-9.</citation>
    <PMID>17020992</PMID>
  </reference>
  <reference>
    <citation>Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46.</citation>
    <PMID>15930316</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fukushima Medical University</investigator_affiliation>
    <investigator_full_name>Takashi Kimura</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

